Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 setmelanotide trial in obesity due to specific MC4R-pathway gene variants
NL-OMON54472Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setmelanotide in Melanocortin-4 receptor pathway diseases and hyperphagia (3 arms), sponsored by Rhythm Pharmaceuticals. Started Oct 2022; status: completed.
02
Drugs
setmelanotide
03
Conditions
Melanocortin-4 receptor pathway diseaseshyperphagia
Beyond the preview
Go deeper on NL-OMON54472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54472.